A neurobehavioral screening of the ckr mouse mutant: Implications for an animal model of schizophrenia

Brain Research Bulletin

Volumn 62, Issue 4, 2004, Pages 315-326

  Torres, German ^a   Hallas, Brian H ^a   Vernace, Vita A ^b   Jones, Craig ^c   Gross, Kenneth W ^c   Horowitz, Judith M ^c,d  

^a NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d MEDAILLE COLLEGE   (United States)

Author keywords

Circling behavior; Clozapine; Dopamine; Lateral ventricles; N methyl D aspartate receptors; Olanzapine

Indexed keywords

ACETYLCHOLINE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DIZOCILPINE; DIZOCILPINE MALEATE; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NITRIC OXIDE SYNTHASE; OLANZAPINE; RENIN;

AGENESIS; ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETICS; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; LATERAL BRAIN VENTRICLE; MALE; METHODOLOGY; MOTOR ACTIVITY; MOUSE; MOUSE STRAIN; MUTANT; MUTATION; NEOSTRIATUM; NERVE FIBER; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; TRANSGENIC MOUSE; WILD TYPE;

EID: 0346095181     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2003.09.020     Document Type: Article

References (38)

1. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA. 97:2000;8104-8109.
2. Breier A., Hamilton S.H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry. 45:1999;403-411.
3. Brzutowic L.M., Hodgkinson K.A., Chow E., Honer W.G., Bassett A.S. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science. 288:2000;678-680.
4. Church G.M., Gilbert W. Genomic sequencing. Proc. Natl. Acad. Sci. USA. 81:1984;1991-1995.
5. Duncan G.E., Sheitman B.B., Leiberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Rev. 29:1999;250-264.
6. Egan M.F., Weinberger D.R. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7:1997;701-707.
7. 2 receptors in the chakragati mouse: neurobehavioral dysfunction in a transgenic insertional mutant. Brain Res. 580:1992;18-26.
8. Fitzgerald L.W., Ratty A.K., Teitler M., Gross K.W., Glick S.D. Specificity of behavioral and neurochemical dysfunction in the chakragati mouse: a novel genetic model of a movement disorder. Brain Res. 608:1993;247-258.
9. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533.
10. Harrison P.J. Schizophrenia: a disorder of neurodevelopment? Curr. Opinion Neurobiol. 7:1997;285-289.
11. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 122:1999;593-624.
12. Hof, P.R., Young, W.G., Bloom, F.E., Belichenko, P.V., Celio, M.R. Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/Sv Mouse Brains. New York: Elsevier, New York, 2001.
13. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacol. 120:1995;128-133.
14. Kim J.S., Kornhuber J.J., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenia patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
15. Kirkpatrick B., Conley R.C., Kakoyannis A., Reep R.L., Roberts R.C. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse. 34:1999;95-102.
16. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry. 172:1998;110-120.
17. Mansbach R.S. Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur. J. Pharmacol. 202:1991;61-66.
18. Masellis M., Basile V.S., Ozdemir V., Meltzer H.Y., Macciardi F.M., Kennedy J.L. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol. Psychiatry. 47:2000;252-266.
19. Moghaddam, B. Glutamate and schizophrenia. Nature: Sci. Med. March: 22-31, 1999.
20. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1351.
21. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436.
22. Moskowitz D.W. Is angiotensin I-converting enzyme a master disease gene? Diabetes. Tech. Ther. 4:2002;683-711.
23. Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur. J. Pharmacol. 368:1999;1-7.
24. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
25. Picciotto M.R., Wickman K. Using knockout and transgenic mice to study neurophysiology and behavior. Physiol. Rev. 78:1998;1131-1163.
26. Ratty A.K., Fitzgerald L.W., Titeler M., Glick S.D., Mullins J.J., Gross K.W. Circling behavior exhibited by a transgenic insertional mutant. Mol. Brain Res. 8:1990;355-358.
27. A.K. Ratty, K.W. Gross, L.W. Fitzgerald, K.W. Gross, The chakragati mouse: a model for brain dopaminergic dysfunction. In: H.B. Niznik (Ed.), Dopamine Receptors and Transporters: Pharmacology, Structure and Function. Marcel Dekker, New York, 1994.
28. Schmued L., Slikker W. Black-Gold: a simple, high resolution histochemical label for normal and pathological myelin in brain tissue sections. Brain Res. 837:1999;289-297.
29. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiat. 45:1999;17-25.
30. Sharma T., Lancaster E., Lee D., Lewis S., Sigmundsson T., Takei N., Gurling H., Barta P., Pearlson G., Murray R. Brain changes in schizophrenia. Br. J. Psychiat. 173:1998;132-138.
31. Smiraglia D.J., Ratty A.K., Gross K.W. Physical characterization of the chromosomal rearrangements that accompany the transgene mutation in the chakragati mouse mutant. Genomics. 45:1997;562-571.
32. Smiraglia D.J., Wu C., Ellsworth M.K., Ratty A.K., Chapman V.M., Gross K.W. Genetic characterization of the chromosomal rearrangements that accompany the transgene insertion in the chakragati mouse mutant. Genomics. 45:1997;572-579.
33. Swerdlow N.R., Braff D.L., Taaid N., Geyer A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiat. 51:1994;139-154.
34. Torres G., Lee S., Rivier C. Immunocytochemical and in situ hybridization detection of hypothalamic neuropeptides from postmortem unfixed rat brains. Neurosci. Lett. 146:1992;96-100.
35. Torres G., Lee S., Rivier C. Ontogeny of the rat hypothalamic nitric oxide synthase and colocalization with neuropeptides. Mol. Cell. Neurosci. 4:1993;155-163.
36. Vervoort V.S., Beachem M.A., Edwards P.S., Ladd S., Miller K.E., de Mollerat X., Clarkson K., Dupont B., Schwartz C.E., Stevenson R.E., Boyd E., Srivastava A.K. AGTR2 mutations in X-linked mental retardation. Science. 296:2002;2401-2403.
37. Williams N.M., O'Donovan M.C., Owen J.M. Genome scans and microarrays: converging on genes for schizophrenia. Genome Biol. 3:2002;10111-10115.
38. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiat. 155:1998;1661-1670.